Bleeding disorders:
Indications for: RAPLIXA
Adjunct to hemostasis for mild-to-moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques is ineffective or impractical. Use in conjunction with absorbable gelatin sponge or RaplixaSpray device.
Adult Dosage:
See full labeling. Apply to surface of bleeding tissue only; give directly from vial using absorbable gelatin sponge or RaplixaSpray device (max 2 vials per device). Individualize dose based on size of bleeding area; max total dose 3g per surgery. Max surface area (25cm2 [vial] or 50cm2 [RaplixaSpray]): use 0.5g; (50cm2 [vial] or 100cm2 [RaplixaSpray]): use 1g; (100cm2 [vial] or 200cm2 [RaplixaSpray]): use 2g.
Children Dosage:
Not established.
RAPLIXA Contraindications:
Intravascular use. Severe or brisk arterial bleeding. Systemic reactions to human blood products.
RAPLIXA Warnings/Precautions:
For topical use only. Life-threatening thrombosis possible from intravascular application. Monitor BP, pulse, oxygen saturation, end tidal CO2 for signs/symptoms of embolism. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Discontinue immediately if hypersensitivity reactions occur. Pregnancy. Nursing mothers.
RAPLIXA Classification:
Topical hemostatic.
Adverse Reactions:
Procedural pain, nausea, constipation, pyrexia, hypotension; infection, possible antibody formation.
Generic Drug Availability:
NO
How Supplied:
Single-use vial (0.5g, 1g, 2g)—1
